Icecure Medical Ltd

IceCure Medical Ltd. is a commercial stage medical device company. It is engaged in the research, development, and marketing of cryoablation systems, disposables, and technologies based on liquid nitrogen for treating tumors. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Icecure Medical reports revenue growth and regulatory milestones in Q1

Icecure Medical Ltd (ICCM) demonstrated strong revenue growth and regulatory progress in Q1 2024, despite a net loss, reflecting a resilient business outlook.
The company's focus on product development, market acceptance, and strategic planning underscores a commitment to long-term success and sustainability.
Addressing cost management, optimizing pricing strategies, and seizing market opportunities will be crucial for Icecure to enhance profitability and drive growth.

Icecure Medical reports robust Q2 sales growth and FDA progress

Icecure Medical's Q2 2024 performance showcased strong sales growth and improved financial metrics.
While facing challenges such as regulatory processes and leadership continuity, the company's strengths lie in its product acceptance and fundraising success.
Opportunities in FDA approvals and market expansion present avenues for future growth and profitability for Icecure Medical.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Athenex

Avaya Holdings

Use these tips for finding penny stocks to buy in 2022 The post 3 Tips for Identifying Penny Stocks With High Potential appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Tips for Identifying Penny Stocks With High Potential

CAESAREA, Israel , Dec. 20, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the commencement of a proposed public offering of its ordinary shares.

IceCure Medical Ltd. Announces Proposed Public Offering

Shares of IceCure Medical Ltd (NASDAQ:ICCM) went on a tear after a study revealed its ProSense treatment was safe and effective in fighting kidney tumors. ProSense is a liquid nitrogen cryoablation solution that is capable of destroying tumors safely without the need for surgery.

IceCure Medical rockets higher on positive study data showing effectiveness of ProSense kidney tumor treatment

IceCure Medical (NASDAQ: ICCM ) stock is zooming about 300% higher this morning. Furthermore, shares jumped as much as 1,000% yesterday after the market closed.

Why Is IceCure Medical (ICCM) Stock Up 300% Today?

IceCure Medical, a little-known medical device company surged in after-hours trading Monday. IceCure's Prosense technology proved to be a safe and effective treatment for cancerous kidney tumors.

1,000% Move in a Day: Medical Stock Soars on Positive Data

ICESECRET study interim findings presented at the Urological Association Conference in Eilat, Israel ProSense was found to be a safe and effective treatment method for renal lesions smaller than 5 cm in patients not suitable for kidney-preserving surgery ProSense is approved for the treatment of benign and malignant kidney tumors in the U.S., Europe, and numerous other countries CAESAREA, Israel , Dec. 19, 2022 /PRNewswire/ --- IceCure Medical Ltd . (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense ® System that destroys tumors by freezing, today announced interim results from the ICESECRET study for the treatment of patients with small renal masses ("SRM") who cannot be offered kidney-preserving surgery.

IceCure's ProSense Safe and Effective in Treating Kidney Tumors with 89.5% Recurrence-Free Rate Based on Interim Study Results

Galit Bar Malik promoted to VP of Operations and Service CAESAREA, Israel , Dec. 6, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the appointment of Vincent Chun Hung Chan to serve as an independent director on the Company's board of directors.

IceCure Appoints Vincent Chun Hung Chan to Serve as an Independent Director on its Board of Directors

IceCure Medical Ltd (NASDAQ:ICCM ) Q3 2022 Results Conference Call December 2, 2022 8:00 AM ET Company Participants Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer Hania Bednarski - Oncoplastic Breast Surgeon and Cryoablation Specialist Conference Call Participants Ben Haynor - Alliance Global Partners Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Welcome to IceCure's Conference Call on the Financial Results for the Nine Months Ended September 30, 2022, and update on recent operational highlights. Management will provide an overview of IceCure's financial results as well as clinical, commercial and operational highlights.

IceCure Medical Ltd (ICCM) Q3 2022 Earnings Call Transcript

Conference call is scheduled for 8:00 a.m. EST today with guest speaker Dr. Hania Bednarski, oncoplastic breast surgeon and cryoablation specialist skilled in using the ProSense System Regulatory filings submitted in the United States for ProSense for treatment in breast cancer Achievement of Medicare coverage code for case-by-case reimbursement Regulatory approval received in Brazil for ProSense cryoprobes and introducers for treatment in several indications Regulatory filings submitted in Canada and Vietnam for ProSense for treatment in numerous indications CAESAREA, Israel , Dec. 5, 2022 /PRNewswire/ -- IceCure Medical Ltd.

IceCure Medical Reports Financial Results for the Nine Months Ended September 30, 2022 and Provides Update on Recent Operational Highlights

Dr. Kenneth Tomkovich Presents: "To Freeze Or Not To Freeze? That Is The Question: Cryoablation For The Treatment Of Breast Cancer" Increasing interest among breast and interventional radiologists in performing breast tumor cryoablation CAESAREA, Israel , Nov. 30, 2022 /PRNewswire/ --  IceCure Medical Ltd.

IceCure's ProSense Featured in Poster Presentation at Radiological Society of North America's 2022 Annual Meeting

CAESAREA, Israel , Nov. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:00 a.m.

TIME CHANGE: IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

CAESAREA, Israel , Nov. 28, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the nine months ended September 30, 2022 on Monday, December 5, 2022 with a press release issued at 7:30 a.m.

IceCure Medical to Report Financial Results for the 9-Month Period Ended September 30, 2022 and Conduct Conference Call on December 5, 2022

Wish

Exela Technologies

Are you buying Reddit penny stocks right now? The post Are Reddit Penny Stocks Worth Buying in 2022?

Are Reddit Penny Stocks Worth Buying in 2022? 3 Reasons

IceCure Medical (NASDAQ: ICCM ) stock is taking off on Tuesday as investors react to an update for Medicare coverage of breast cancer patients. The big news investors need to know about is the Centers for Medicare & Medicaid Services assigning ProSense “CPT Category III code 0581T to ambulatory payment classification 5091, Level 1 Breast/Lymphatic Surgery and Related Procedures.

What Is Going on With IceCure Medical (ICCM) Stock Today?

Receives assignment to a Medicare Payment Group for hospital outpatient payment Marks CMS's first payment assignment for cryoablation of breast cancer Code and preliminary payment amount for facility fee will be effective January 1, 2023, which together may lead to a coverage policy subject to receipt of FDA marketing authorization  Filed De Novo Classification with FDA for breast cancer marketing authorization in October 2022 CAESAREA, Israel , Nov. 8, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced the Centers for Medicare & Medicaid Services ("CMS") assigned its ProSense breast cancer cryoablation procedures with CPT Category III code 0581T to ambulatory payment classification  5091, Level 1 Breast/Lymphatic Surgery and Related Procedures.

IceCure's ProSense® Achieves Significant Milestone in Medicare Coverage of Breast Cancer Procedures

ProSense® minimally invasive breast cancer procedure destroys tumors, freezing cancer in its tracks, empowering women to walk out of the procedure and back to their lives CAESAREA, Israel , Oct. 26, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today reported on its Breast Cancer Awareness Month activities in clinics, training physicians, supporting patients, and exhibiting at industry conferences across the globe, including the launch of its campaign: #FreezeCancerNotYourLife   ProSense cryoablation provides women a minimally invasive in-office procedure for the treatment of breast cancer* with little to no downtime, minimal pain, only local anesthesia and no scarring.

IceCure Launches Global #FreezeCancerNotYourLife Movement During Breast Cancer Awareness Month

43,000 cases estimated annually in the U.S. alone for indication in initial filing representing an estimated $80 million annual addressable market   65,000 cases estimated annually in the U.S. for broader indication Company intends to file based on FDA's guidance, reflecting the full ICE3 study population after ICE3 5-year follow-ups are completed for all patients in 2024 To date, the Ipsilateral Breast Tumor Recurrence (IBTR) rate for the entire study population is 3.09% Submission data include IBTR as the primary endpoint CAESAREA, Israel , Oct. 19, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing, today announced it submitted a regulatory filing (De Novo Classification Request) with the U.S. Food and Drug Administration ("FDA") for marketing authorization based on ICE3 clinical trial ("ICE3") interim analysis of ProSense for the indication of early-stage (Luminal A T1 invasive) low-risk breast cancer in patients who are at high risk to surgery (not suitable for surgical alternatives), representing approximately 43,000 women in the U.S. annually.

IceCure Files De Novo Classification Request with the FDA for Marketing Authorization of ProSense® with Breakthrough Indication: Early-Stage Low-Risk Breast Cancer Patients at High Risk to Surgery

Regulatory filing submitted by KTRFIOS, IceCure's distributor in Brazil ProSense Cryoablation System approval in Brazil is pending $6.6 million in expected sales during the five years following full regulatory approval, per distribution agreement CAESAREA, Israel , Oct. 11, 2022 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) (TASE: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System, that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its ProSense Cryoprobes and Introducers have received regulatory approval from the Brazilian Health Regulatory Agency ("ANVISA").

IceCure Medical's ProSense® Cryoprobes and Introducers Receive Regulatory Approval in Brazil

Company is rapidly expanding its global regulatory and commercial reach CAESAREA, Israel , Aug. 29, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has submitted a regulatory filing with the Department of Medical Equipment and Construction ("DMEC") of Vietnam's Ministry of Health for the ProSense System and accessories.

IceCure Submits Regulatory Filing in Vietnam for Approval of ProSense®

IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Eyal Shamir – Chief Executive Officer Ronen Tsimerman – Chief Financial Officer Kenneth Tomkovich – Co-Primary Investigator Conference Call Participants Ben Haynor – Alliance Global Partners Kemp Dolliver – Brookline Capital Markets Operator Welcome to IceCure's Conference Call on the Financial Results for the First Half of 2022. Management will provide an overview of IceCure's financial results as well as clinical, commercial, and operational highlights.

IceCure Medical Ltd's (ICCM) CEO Eyal Shamir on Q2 2022 Results - Earnings Call Transcript

Medtronic

Conference call scheduled for 4:30 p.m. EDT today Exclusive distribution agreement signed with Shanghai Medtronic Zhikang Medical Devices Co. Ltd.

IceCure Medical Reports Financial Results for the First Half of 2022 and Recent Operational Highlights

CAESAREA, Israel , Aug. 9, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m.

IceCure Medical to Report H1 2022 Results and Conduct Conference Call on August 15, 2022

Canadian hospitals and health care providers have expressed strong interest in ProSense® as they seek minimally invasive treatments for breast and other tumors CAESAREA, Israel , July 25, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System ( "ProSense") that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the submission of a regulatory filing with the Canadian governmental agency, Health Canada, for approval of IceCure's ProSense System and its cryoprobes for the treatment of numerous indications including: Oncology – ablation of benign and malignant breast tumors as well as benign and malignant tumors of the lung, liver, and musculoskeletal system, and for palliative intervention; Urology – ablation of renal cell carcinoma; Thoracic surgery – ablation of cancerous lesions in the lung tissue; and Other indications and for general surgery.

IceCure Announces Regulatory Filing Submission for Approval of ProSense® in Canada for Indications Including Ablation of Benign and Malignant Breast Tumors

A global medical device industry expert with a focus on market creation and fast growth, Mr. Glick has led Itamar Medical, Inc. ("Itamar Medical") as CEO, building its medical device business for a decade until Itamar Medical's acquisition by Zoll Medical for $538 million CAESAREA, Israel , July 5, 2022 /PRNewswire/ -- IceCure Medical Ltd.

Former Itamar Medical CEO & President Gilad Glick Joins IceCure Medical as a Strategic Advisor for Global Go-To-Market Operations

Strong interest in ProSense from potential customers and distributors spurred by categorical course and Shanghai Medtronic deal CAESAREA, Israel , June 15, 2022 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of minimally-invasive cryoablation technology, the ProSense® System that destroys tumors by freezing as an alternative to surgical tumor removal, today announced ProSense was featured in a categorical course titled "Cryoablation for the Treatment of Breast Cancer: Breast Interventions for the Interventionalist" on Tuesday, June 14, 2022 at the Society of Interventional Radiology (SIR) Annual Scientific Meeting in Boston ("SIR 2022 Conference").

News for Icecure Medical Ltd Stock (ICCM)